By AIM · AIM Media House
Pharma leader Eli Lilly has invested in healthcare AI company Abridge as the companies work to apply ambient clinical documentation technology to clinical trial recruitment, according to announcements from Abridge and reporting by STAT and Endpoints.
The investment extends Abridge's role beyond medical documentation and into research operations. The Pittsburgh-based company is known for software that records and structures physician-patient conversations into clinical notes and electronic health record workflows.
It now plans to use the same technology to help identify patients who may qualify for clinical trials. Abridge announced the collaboration during a broader product expansion that also included new partnerships with NVIDIA and other healthcare technology providers.
The move reflects growing interest among pharmaceutical companies in using AI to address one of the industry's most persistent challenges: finding eligible patients for clinical studies.
According to Endpoints , Lilly's investment is tied to efforts to improve trial recruitment by identifying potential participants from clinical conversations and medical records.
From Documentation to Research Workflows Abridge was founded in 2018 and initially focused on reducing clinician documentation workloads through ambient AI technology. The company raised a $150 million Series C round in 2024 and has since expanded its presence across U.S. health systems.
Its technology listens to physician-patient conversations, generates structured documentation, and integrates information into clinical workflows. That foundation helped drive deployments across major healthcare organizations and partnerships with electronic health record providers.
The company's evolution mirrors broader activity across the healthcare AI sector.
Continue on AIM Media House